Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT05219513
Title A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7443904 in Combination With Glofitamab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Hoffmann-La Roche

hematologic cancer


Obinutuzumab + RO7082859 + RO7443904 + Tocilizumab

Obinutuzumab + RO7082859 + RO7443904

Age Groups: senior | adult
Covered Countries ITA

No variant requirements are available.